Correlation Between Aerovate Therapeutics and Recursion Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and Recursion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and Recursion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and Recursion Pharmaceuticals, you can compare the effects of market volatilities on Aerovate Therapeutics and Recursion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of Recursion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and Recursion Pharmaceuticals.

Diversification Opportunities for Aerovate Therapeutics and Recursion Pharmaceuticals

-0.42
  Correlation Coefficient

Very good diversification

The 3 months correlation between Aerovate and Recursion is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and Recursion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Recursion Pharmaceuticals and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with Recursion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Recursion Pharmaceuticals has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and Recursion Pharmaceuticals go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and Recursion Pharmaceuticals

Given the investment horizon of 90 days Aerovate Therapeutics is expected to under-perform the Recursion Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Aerovate Therapeutics is 3.88 times less risky than Recursion Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Recursion Pharmaceuticals is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  713.00  in Recursion Pharmaceuticals on December 4, 2024 and sell it today you would lose (54.00) from holding Recursion Pharmaceuticals or give up 7.57% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Aerovate Therapeutics  vs.  Recursion Pharmaceuticals

 Performance 
       Timeline  
Aerovate Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Aerovate Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Recursion Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Recursion Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Recursion Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Aerovate Therapeutics and Recursion Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Aerovate Therapeutics and Recursion Pharmaceuticals

The main advantage of trading using opposite Aerovate Therapeutics and Recursion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, Recursion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Recursion Pharmaceuticals will offset losses from the drop in Recursion Pharmaceuticals' long position.
The idea behind Aerovate Therapeutics and Recursion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data